CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hansoh Pharma's dalmelitinib-aumolertinib improves progression-free survival in Phase 3 lung cancer trial

By Public Technologies
  • Hansoh Pharma presented Phase 3 results for dalmelitinib combined with aumolertinib at the ESMO Congress on October 26, 2026.
  • The combination significantly delayed disease progression versus platinum-based chemotherapy in advanced non-small cell lung cancer with EGFR mutations and MET amplification.
  • The trial met its primary endpoint in patients whose disease progressed following EGFR inhibitor therapy.
  • China's National Medical Products Administration accepted the combination's new drug application on February 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk